SCHEMBL350733

SCHEMBL350733

C#Cc1ccc(CC#N)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.38
CYP2A6 P11509 1/20 0.38
KMT2A Q03164 1/20 0.38
HDAC8 Q9BY41 2/20 0.37
KDM4E B2RXH2 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
FFAR1 O14842 1/20 0.35
ENPP2 Q13822 1/20 0.34
TNF P01375 1/20 0.34
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
CTSS P25774 1/20 0.34
PKM P14618 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154504 0.82 KMT2A (0.47) LOXL2CYP2A6KMT2AKDM4ETDP1
SCHEMBL249189 0.80 LOXL2 (0.58) LOXL2CYP2A6CA12CA2CA9
SCHEMBL16216302 0.74 MMP2 (0.42) LOXL2CYP2A6KMT2AKDM4EL3MBTL1
SCHEMBL4432425 0.74 ENPP2 (0.50) KMT2AKDM4ETDP1CA12CA1
SCHEMBL23137321 0.74 MMP3 (0.50) KMT2AKDM4ETDP1L3MBTL1ENPP2
SCHEMBL5179689 0.74 HDAC8 (0.43) HDAC8CA12CA1CA2CA4
SCHEMBL196175 0.74 MMP3 (0.50) KMT2AKDM4ETDP1L3MBTL1ENPP2
SCHEMBL8763328 0.74 KMT2A (0.42) LOXL2KMT2AKDM4ETDP1L3MBTL1
SCHEMBL3840593 0.74 HDAC8 (0.43) LOXL2CYP2A6HDAC8TDP1CA12
SCHEMBL10191895 0.73 CYP1A1 (0.43) LOXL2CYP2A6KMT2AKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118459508-A Iridium complex for inducing Mutp to degrade and preparation method and application thereof 南京师范大学 2024-08-09 CN claimed
CN-115874199-B In D2Functionalized deuterated olefin compound with O as deuterium source, and preparation method and application thereof 天津大学 2024-06-04 CN claimed
CN-117964614-A 2,4,6 Substituted quinoline derivative and application thereof 三峡大学 2024-05-03 CN claimed
CN-113845481-B Synthesis method of 4, 4-dimethyl-4, 5-dihydropyridazin-3-one 泉州师范学院 2023-05-30 CN claimed
CN-115874199-A With D 2 Functional deuterated olefin compound with O as deuterium source and preparation method and application thereof 天津大学 2023-03-31 CN claimed
CN-113845481-A Synthesis method of 4, 4-dimethyl-4, 5-dihydropyridazin-3-one 泉州师范学院 2021-12-28 CN claimed
CN-112391645-B Synthesis method for preparing alpha, alpha-dibromo-ketone by electrochemically oxidizing alkyne and bromide 武汉大学 2021-09-14 CN claimed
CN-112391645-A Synthesis method for preparing alpha, alpha-dibromo-ketone by electrochemically oxidizing alkyne and bromide 武汉大学 2021-02-23 CN claimed
CN-118580134-A Preparation method of 1, 3-eneyne GEM isomer 安徽大学 2024-09-03 CN disclosed
CN-118459508-A Iridium complex for inducing Mutp to degrade and preparation method and application thereof 南京师范大学 2024-08-09 CN disclosed
CN-115874199-B In D2Functionalized deuterated olefin compound with O as deuterium source, and preparation method and application thereof 天津大学 2024-06-04 CN disclosed
US-20230174965-A1 METHODS AND PRODUCTS UNIV BIRMINGHAM (GB) 2023-06-08 US disclosed
CN-113845481-B Synthesis method of 4, 4-dimethyl-4, 5-dihydropyridazin-3-one 泉州师范学院 2023-05-30 CN disclosed
CN-115874199-A With D 2 Functional deuterated olefin compound with O as deuterium source and preparation method and application thereof 天津大学 2023-03-31 CN disclosed
CN-101001842-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-07-18 CN disclosed
EP-1756063-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-02-28 EP disclosed
US-20050282858-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-22 US disclosed
WO-2005110992-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2005-11-24 WO disclosed
EP-1537135-A2 ADENOSINE A3 RECEPTOR AGONISTS CV THERAPEUTICS, INC. (US) 2005-06-08 EP disclosed
WO-2004022573-A2 ADENOSINE A3 RECEPTOR AGONISTS CV THERAPEUTICS, INC. (US) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282858-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 LOXL2 3172/4885CYP2A6 283/4885KMT2A 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.